TenNor Therapeutics possesses a strong R&D portfolio through the acquisition of assets from Cumbre and patents from the TB Alliance. Major development candidates include three dual-action molecules with distinct mechanisms of action:
These dual-action molecules are active against bacterial strains that are resistant to current antibiotics. They have a low propensity for resistance development. and the potential to revolutionize the treatment of digestive diseases associated with bacterial infections.
Target indications include:
H. pylori infection
C. difficile infection
Small intestinal bacterial overgrowth
TenNor's drug development engine is further fueled by a unique dual-action molecule R&D platform. The company possesses a novel library of isogenic bacterial strains with resistant mutations on key drug targets. This strain collection is being utilized to rapidly screen and advance dual-action drug candidates.